Trial Profile
Open label study to assess efficacy and safety of the fully human anti tumour necrosis factor alpha monoclonal antibody adalimumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROWD
- Sponsors Abbott Laboratories
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 13 Jun 2009 Results were reported at the 2009 EULAR.
- 16 Apr 2008 New trial record.